Timon Vandamme
@timonv
MD PhD, Digestive oncologist @UZAnieuws, ass. prof. @UAntwerpen, senior clinical investigator @FWOvlaanderen, coordinator @enetwerkbe, secretary @dbnetsociety
ID: 72263340
07-09-2009 11:39:52
894 Tweet
297 Takipçi
359 Takip Edilen
🌟 Day 3 at #ENETS2024: Prof Timon Vandamme explores the cutting-edge of PRRT in NET care. Discover the latest in treatment strategies and diagnostic imaging that are redefining patient outcomes. Dive into the full overview: bit.ly/3J7EghJ #NeuroendocrineTumours
🌟NETTER-2 Study shines at #ENETS2024: Prof Timon Vandamme reviews PRRT's unprecedented impact in high-grade NET treatment. A first in first-line care, revealing a path for enhanced patient outcomes. #NeuroendocrineTumours #OncologyResearch #MediMix
✅ Switching to 2nd line after #IO should be considered in toxicity or disease progression Do you know which 2nd line treatment options are approved in advanced #HCC? Watch the experts knowledge share by Ducreux Michel, Timon Vandamme & Changhoon Yoo, MD👇 ow.ly/7wYi50R46a5 #MedEd
🔥 What would you do in case of slow progression under #IO based treatment for a patient with advanced #HCC? Check out the interactive patient case video from Timon Vandamme to follow a patient's journey & discuss when to switch to 2nd line👇 ow.ly/h7KL50RuPcX #MedEd
✅ TKIs are recommended treatments for #HCC patients who are not eligible for #IO first line Do know what patient groups this includes? Find out in the webinar replay of our experts knowledge share by Ducreux Michel, Timon Vandamme & Changhoon Yoo, MD👇 ow.ly/Qxnu50RUCNI #MedEd
Lack of awareness and management of conflict of interest among oncologists - splendid presentation by Khalid El Bairi on results of the ONCOTRUST-1 pilot study. Looking forward to ONCOTRUST-2. #globaloncology #ASCO24
CD40 agonist mitazalimab with mFOLFIRINOX in mPDAC. Promising data published in Lancet Oncol. We keep fighting against this disease. # ASCO24; Vall d’Hebron Institute of Oncology (VHIO) The Lancet Oncology
💡 There is a lack of solid evidence for optimal 2nd line regimens after progression of advanced #HCC Do you know what 2nd line treatment options have been approved? Find out in the webinar replay by Ducreux Michel, Timon Vandamme & Changhoon Yoo, MD👇 ow.ly/K4CR50Sz3Tj #MedEd #IO
🚨 New Videos on PRRT for Neuroendocrine Tumors (NET)! Prof Chris Verslype, Prof Timon Vandamme & Prof Christophe Deroose discuss the latest breakthroughs in PRRT and future therapies like Actinium-225.
Hans Prenen #ESMO24 concomitant paper: Adrian Sacher, M.D. presents the First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor at today's Presidential Symposium Hans Prenen